Cure8 research brief
Why This Matters
People with IBD, especially older adults on biologic immunosuppression, may be at higher risk for unusual bloodstream infections and complications such as possible endocarditis. Awareness can prompt timely imaging, blood cultures, and adjustments to immunosuppressive therapy.
Who Should Pay Attention
Adults with IBD (especially older patients) on biologic therapy, gastroenterologists, infectious disease clinicians, and hospital-based clinicians evaluating bacteremia.
Study Snapshot
What To Know
Older adults with IBD on immunosuppressive biologic therapy can develop uncommon bloodstream infections.
This article reports a case of Aggregatibacter aphrophilus bacteremia in a 70-year-old man with ulcerative colitis receiving adalimumab; imaging showed multifocal hemangiomatosis and a probable septic embolus, and the patient improved after intravenous ceftriaxone and stopping adalimumab.
This case highlights two practical points: clinicians should keep a broad microbiologic differential for bacteremia in immunosuppressed IBD patients, and standard tests like transesophageal echocardiography may be precluded by anatomic findings (here an esophageal hemangioma), so alternative cardiac imaging and application of the 2023 Duke-ISCVID criteria can be important.
For this patient, IBD therapy was changed from adalimumab to mesalamine with clinical remission reported after discharge.
Keep In Mind
This is a single case report (abstract-level summary provided). It describes one patient and cannot establish frequency or causal risk; it illustrates diagnostic challenges and management decisions rather than proving broader associations.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.